| pubmed-article:8492939 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8492939 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:8492939 | lifeskim:mentions | umls-concept:C0021027 | lld:lifeskim |
| pubmed-article:8492939 | lifeskim:mentions | umls-concept:C0039082 | lld:lifeskim |
| pubmed-article:8492939 | lifeskim:mentions | umls-concept:C0035020 | lld:lifeskim |
| pubmed-article:8492939 | lifeskim:mentions | umls-concept:C0001758 | lld:lifeskim |
| pubmed-article:8492939 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:8492939 | pubmed:dateCreated | 1993-6-11 | lld:pubmed |
| pubmed-article:8492939 | pubmed:abstractText | Seven adult patients received human immune globulin intravenously as initial therapy for Guillain-Barré syndrome. Although all patients initially stabilized or improved, five patients deteriorated 1 to 16 days after completion of treatment. In all five patients, clinical worsening included loss of at least one functional grade together with a decreased forced vital capacity. We subsequently treated each patient with a course of plasma exchange, which led to varying degrees of clinical improvement in four. In contrast to previously reported relapse rates for Guillain-Barré syndrome, our experience suggests that clinically significant relapses may occur in patients more often following human immune globulin therapy than after either plasma exchange or no therapy. | lld:pubmed |
| pubmed-article:8492939 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8492939 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8492939 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8492939 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8492939 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:8492939 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8492939 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8492939 | pubmed:month | May | lld:pubmed |
| pubmed-article:8492939 | pubmed:issn | 0028-3878 | lld:pubmed |
| pubmed-article:8492939 | pubmed:author | pubmed-author:HanleyD FDF | lld:pubmed |
| pubmed-article:8492939 | pubmed:author | pubmed-author:ChaudhryVV | lld:pubmed |
| pubmed-article:8492939 | pubmed:author | pubmed-author:CornblathD... | lld:pubmed |
| pubmed-article:8492939 | pubmed:author | pubmed-author:BorelCC | lld:pubmed |
| pubmed-article:8492939 | pubmed:author | pubmed-author:IraniD NDN | lld:pubmed |
| pubmed-article:8492939 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8492939 | pubmed:volume | 43 | lld:pubmed |
| pubmed-article:8492939 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8492939 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8492939 | pubmed:pagination | 872-5 | lld:pubmed |
| pubmed-article:8492939 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8492939 | pubmed:meshHeading | pubmed-meshheading:8492939-... | lld:pubmed |
| pubmed-article:8492939 | pubmed:meshHeading | pubmed-meshheading:8492939-... | lld:pubmed |
| pubmed-article:8492939 | pubmed:meshHeading | pubmed-meshheading:8492939-... | lld:pubmed |
| pubmed-article:8492939 | pubmed:meshHeading | pubmed-meshheading:8492939-... | lld:pubmed |
| pubmed-article:8492939 | pubmed:meshHeading | pubmed-meshheading:8492939-... | lld:pubmed |
| pubmed-article:8492939 | pubmed:meshHeading | pubmed-meshheading:8492939-... | lld:pubmed |
| pubmed-article:8492939 | pubmed:meshHeading | pubmed-meshheading:8492939-... | lld:pubmed |
| pubmed-article:8492939 | pubmed:meshHeading | pubmed-meshheading:8492939-... | lld:pubmed |
| pubmed-article:8492939 | pubmed:meshHeading | pubmed-meshheading:8492939-... | lld:pubmed |
| pubmed-article:8492939 | pubmed:meshHeading | pubmed-meshheading:8492939-... | lld:pubmed |
| pubmed-article:8492939 | pubmed:meshHeading | pubmed-meshheading:8492939-... | lld:pubmed |
| pubmed-article:8492939 | pubmed:meshHeading | pubmed-meshheading:8492939-... | lld:pubmed |
| pubmed-article:8492939 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8492939 | pubmed:articleTitle | Relapse in Guillain-Barré syndrome after treatment with human immune globulin. | lld:pubmed |
| pubmed-article:8492939 | pubmed:affiliation | Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD. | lld:pubmed |
| pubmed-article:8492939 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8492939 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8492939 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8492939 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8492939 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8492939 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8492939 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8492939 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8492939 | lld:pubmed |
